Urinary placental growth factor determined in the first trimester of pregnancy as a predictor of preeclampsia

2020 ◽  
Vol 21 ◽  
pp. 63-67
Author(s):  
Akylbek Tussupkaliyev ◽  
Andrey Gaiday ◽  
Saule Bermagambetova ◽  
Sholpan Arenova ◽  
Lyazzat Kaldigulova ◽  
...  
Keyword(s):  
Growth Factor ◽  
First Trimester ◽  
Placental Growth Factor ◽  
First Trimester Of Pregnancy

scholarly journals Clinical and Pathogenetic Causes of Developing Complications in Multiple Pregnancy

2020 ◽  
Vol 27 (1) ◽  
pp. E202016
Author(s):  
Iryna Nikitina ◽  
Volodymyr Boiko ◽  
Tetiana Babar ◽  
Natalia Kalashnik ◽  
Nataliia Ikonopistseva ◽  
...  
Keyword(s):  
Growth Factor ◽  
Pregnant Women ◽  
Multiple Pregnancy ◽  
First Trimester ◽  
Placental Growth Factor ◽  
Enzyme Linked Immunosorbent Assay ◽  
Full Time ◽  
Singleton Pregnancy ◽  
Placental Dysfunction ◽  
First Trimester Of Pregnancy

To assess the role of the placental growth factor in the development of gestational complications during multiple pregnancy, there was conducted a study of this indicator in serum of 320 pregnant women with multiple pregnancy in the first trimester and 40 pregnant women with singleton pregnancy (the control group).          The objective of the research was to study the effect of placental growth factors on the gestational process in multiple pregnancy.          Materials and Methods. There was conducted a prospective study of pregnancy and childbirth in 320 females with multiple pregnancy (the main group) and 40 healthy women with singleton pregnancy. The level of serum placental growth factor was determined by enzyme-linked immunosorbent assay using monoclonal antibodies in the first trimester of pregnancy. The indicators of the hemostasis system (vascular, platelet and coagulation components) were evaluated according to generally accepted methods. Doppler ultrasound of the placental and fetal blood flow was performed in the uterine arteries, the umbilical artery and vein, the fetal middle cerebral artery.          Results. Women with multiple pregnancy were at high risk of developing gestational complications such as preterm deliveries (67.8%, p<0.01), placental dysfunction, pre-eclampsia (17.5%, p<0.05). The disorders of the vascular platelet and coagulation hemostasis in the first trimester of pregnancy were the main risk factors for early termination of pregnancy. Low level of serum placental growth factor in pregnant women with multiple pregnancy in case of preterm delivery, placental dysfunction and pre-eclampsia (111.23 ± 8.4, 203.24 ± 6.4 and 305.86 ± 7.4 pg/ml), in comparison with the corresponding indicators in singleton pregnancy (418.2 ± 10.4 pg/ml), was proven to be a prognostic marker for the development of gestational complications.          Conclusions. Timely correction of gestational complications in multiple pregnancy with micronized progesterone, low molecular weight heparins, angio-protective agents allowed us to prolong pregnancy with monochorionic placentation type for 3.2 weeks (up to 34.2 ± 2.4 weeks) and provide full-time delivery of dichorionic twin pregnancy.

P-029. Role of Placental growth factor for prediction of preeclampsia in first trimester of pregnancy

2021 ◽  
Vol 25 ◽  
pp. e38
Author(s):  
Manju Lata Verma ◽  
Uma Singh ◽  
Vandana Solanki ◽  
Rekha Sachan ◽  
Pushp L Sankhwar
Keyword(s):  
Growth Factor ◽  
First Trimester ◽  
Placental Growth Factor ◽  
First Trimester Of Pregnancy

First-trimester maternal serum metastin, placental growth factor and chitotriosidase levels in pre-eclampsia

2012 ◽  
Vol 164 (2) ◽  
pp. 146-149 ◽  
Author(s):  
Riza Madazli ◽  
Berk Bulut ◽  
Abdullah Tuten ◽  
Burcu Aydin ◽  
Gökhan Demirayak ◽  
...  
Keyword(s):  
Growth Factor ◽  
First Trimester ◽  
Maternal Serum ◽  
Placental Growth Factor

scholarly journals Serum placental growth factor in late first trimester of pregnancy for prediction of preeclampsia in primigravida - a case control study

2016 ◽  
Vol 6 (1) ◽  
pp. 106
Author(s):  
Rachna Agarwal ◽  
Shweta Chaudhary ◽  
Rajarshi Kar ◽  
Gita Radhakrishnan ◽  
Richa Sharma
Keyword(s):  
Case Control Study ◽  
Gestational Hypertension ◽  
Final Analysis ◽  
First Trimester ◽  
Case Control ◽  
Placental Growth Factor ◽  
Serum Samples ◽  
First Trimester Of Pregnancy ◽  
Nested Case Control ◽  
Control Study

Background: We studied the correlation of serum PLGF levels at 11-14 weeks in primigravida for prediction of future preeclampsia in a prospective nested case control study and estimated the critical levels of PLGF for possible use as screening test.Methods: Subjects with preeclampsia/gestational hypertension were taken as cases with an equal number of controls.Results: Out of 300 participants, final analysis was possible in 291 subjects. Thirty five were cases; two had early PE, 15 late PE and 18 had GH. PLGF level was lower in cases (20 pg/ml) compared to controls (79 pg/ml). PLGF was significantly lower in PE cases (15 pg/ml) compared to GH cases (34 pg/ml). PLGF had maximum area under the ROC curve (AUC) for PE with value of 0.867. Further, late PE had more AUC (0.853) as compared to GH (0.759). The cut off value for prediction of PE was found to be <30 pg/ml with 88.2% sensitivity and 71.4% specificity.Conclusions: PLGF levels were significantly lower in first trimester serum samples of subjects who later developed either preeclampsia or gestational hypertension. PLGF had better detection rate for PE and late PE as compared to GH.

Maternal serum placental growth factor and α -fetoprotein testing in first trimester screening for Down syndrome

2013 ◽  
Vol 33 (5) ◽  
pp. 457-461 ◽  
Author(s):  
Kim Donalson ◽  
Steve Turner ◽  
Lesley Morrison ◽  
Päivi Liitti ◽  
Christel Nilsson ◽  
...  
Keyword(s):  
Down Syndrome ◽  
Growth Factor ◽  
First Trimester ◽  
Maternal Serum ◽  
Placental Growth Factor ◽  
First Trimester Screening ◽  
Trimester Screening

First-trimester Placental Protein 13 and Placental Growth Factor

2011 ◽  
Vol 31 (4) ◽  
pp. 238
Author(s):  
E.J. Wortelboer ◽  
M.P. Koster ◽  
H.S. Cuckle ◽  
P.H. Stoutenbeek ◽  
P.C. Schielen ◽  
...  
Keyword(s):  
Growth Factor ◽  
First Trimester ◽  
Placental Growth Factor ◽  
Placental Protein

scholarly journals First-Trimester Placental Growth Factor in Screening for Gestational Diabetes

2015 ◽  
Vol 39 (4) ◽  
pp. 287-291 ◽  
Author(s):  
Beatrice Mosimann ◽  
Sophia Amylidi ◽  
Lorenz Risch ◽  
Ute Wiedemann ◽  
Daniel Surbek ◽  
...  
Keyword(s):  
At Risk ◽  
Growth Factor ◽  
Gestational Diabetes ◽  
Glycosylated Hemoglobin ◽  
First Trimester ◽  
Placental Growth Factor ◽  
Serum Concentrations ◽  
Fetal Medicine ◽  
Hba1c Levels ◽  
Do So

Objective: The aim of this study was first to assess whether first-trimester serum concentrations of placental growth factor (PlGF) differ between patients with and without gestational diabetes (GDM) and second to test whether there is a correlation between glycosylated hemoglobin (HbA1c), a factor recently shown to be useful in predicting GDM, and PlGF. Methods: PlGF was measured at 8-14 weeks with the Kryptor Immunoassay Analyzer (Brahms, Berlin, Germany). Absolute values were converted to multiples of the median using the software provided by the Fetal Medicine Foundation London. GDM was diagnosed using internationally accepted criteria. HbA1c levels were quantified using the TOSOH G7 automated hemoglobin analyzer. Results: From January to December 2014, 328 women were included in the study, 51 (15.5%) of whom developed GDM. First-trimester PlGF quantification does not discriminate between women at risk to develop GDM and controls, while HbA1c is able to do so. No correlation was found between PlGF and HbA1c. Conclusion: Our findings do not lend support to the hypothesis that early PlGF values are different in women who later develop GDM.

Sign in / Sign up

Export Citation Format

Share Document